153.70 +1.93 (1.27%)
Pre-Market: 8:32AM EDT
|Bid||146.00 x 1000|
|Ask||156.00 x 800|
|Day's Range||150.01 - 152.39|
|52 Week Range||96.42 - 164.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||173.86|
Although 30 states have legalized cannabis in some capacity, the federal scheduling of pot is a major headache for businesses and medical patients.
Despite generally being a voice of opposition, seniors using medical cannabis for pain relief revealed intriguing results in a new survey.
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / U.S. equities continued to push higher on Monday, as strong economic data counters worries on rising trade tensions. The Dow Jones Industrial Average advanced ...
NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, ...
As Canada marches toward recreational legalization for marijuana, Canopy CEO Bruce Linton is optimistic about marketing beverages and sleep-aids to a broader audience.
VANCOUVER, British Columbia, June 27, 2018-- Isodiol International Inc., a global CBD innovator specializing in hemp-based health and wellness products, the development of pharmaceutical CBD delivery methods ...
- Marijuana de-regulation in Canada, and parts of the U.S., has given rise to the marijuana industry, ...
Monday's FDA approval of GW Pharmaceuticals' new epilepsy drug will lead to other treatments derived from cannabis, says CEO Justin Gover. The medication is being evaluated by the DEA, which must also approve it before it can be sold. On Monday, the Food and Drug Administration approved the company's new epilepsy drug , Epidiolex, the first cannabis-based drug the U.S. regulator has approved.
The DEA must make a final scheduling decision before the drug can be soldDr. The Food and Drug Administration approved the U.S.’s first cannabis-derived drug on Monday, in a move that may make the path to approval clearer for other companies working in the space. The drug, GW Pharmaceuticals’ epidiolex, is intended for seizures associated with two rare types of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
NEW YORK, NY / ACESSWIRE / June 26, 2018 / It was a bad day for PolarityTE shares on Monday after short seller Citron Research asked upon the SEC to "halt this stock immediately" on claims that the company is a "fraud." Shares of GW Pharmaceuticals may have closed in the red yesterday but the company made history as its Epidiolex drug was the first marijuana-based drug to be approved by the FDA in the nation. GW Pharmaceuticals plc shares closed down 4.29% on almost 1.2 million shares traded on Monday.